Every 10-Q that Bicara Therapeutics Inc. (BCAX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BCAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAX filings page.
Bicara Therapeutics Inc. is a clinical-stage oncology company focused on bifunctional antibody therapy ficerafusp alfa for solid tumors, particularly head and neck cancers. It reported a net loss of $55.4 million for the quarter and $111.6 million for the first half of 2026, reflecting heavier investment in R&D and corporate build-out.
Quarterly operating expenses rose to $60.0 million, driven by $45.8 million in research and development and $14.2 million in general and administrative costs, including higher clinical, manufacturing and stock-based compensation expenses. Cash used in operating activities was $81.7 million in the first half.
Bicara strengthened its balance sheet via a February 2026 equity and pre-funded warrant offering, bringing cash, cash equivalents and marketable securities to $497.3 million as of June 30, 2026 and total equity to $468.8 million. Management believes this capital will fund operations into the first half of 2029 while advancing the Phase 2/3 FORTIFI-HN01 pivotal trial and additional studies of ficerafusp alfa.
Bicara Therapeutics reports a larger quarterly loss as it accelerates development of its lead cancer drug ficerafusp alfa. For the three months ended March 31, 2026, net loss was $56.2 million, or $0.93 per share, compared with $36.8 million, or $0.68 per share, a year earlier.
Research and development expenses rose to $47.5 million from $34.3 million, driven by manufacturing and clinical costs for the Phase 2/3 FORTIFI-HN01 pivotal trial and Phase 1/1b studies. General and administrative expenses increased to $12.7 million from $7.5 million as the company expanded headcount and public-company infrastructure.
Cash, cash equivalents and marketable securities totaled $539.8 million as of March 31, 2026, supported by a February 2026 equity and pre-funded warrant offering that generated about $161.8 million in net proceeds. Management believes this liquidity can fund operations into the first half of 2029 while Bicara advances ficerafusp alfa toward potential regulatory milestones.
Bicara Therapeutics (BCAX) reported Q3 2025 results with a net loss of $36.3 million as operating expenses rose to $40.7 million on increased R&D. Research and development totaled $33.0 million (including related-party), reflecting ongoing spend for ficerafusp alfa and the FORTIFI-HN01 program.
Cash, cash equivalents and investments were $407.6 million as of September 30, 2025, supported by short- and long-term U.S. Treasury holdings. Net cash used in operating activities was $82.9 million for the nine months, while interest income contributed $4.4 million in the quarter. The company reported an accumulated deficit of $321.6 million.
Management states existing liquidity is expected to fund operations into the first half of 2029. As a subsequent event, Bicara filed a Form S-3 shelf for up to $400.0 million and established an ATM program of up to $150.0 million; no sales have occurred. Shares outstanding were 54,781,950 as of November 5, 2025.
Bicara Therapeutics is a clinical-stage biopharmaceutical company advancing its lead bifunctional antibody, ficerafusp alfa, into late-stage testing. The company reported $436.6 million in cash and cash equivalents as of June 30, 2025 and an accumulated deficit of $285.3 million. Net losses were $27.4 million for the quarter and $64.2 million for the six months ended June 30, 2025, driven by higher research and development and general and administrative spending as Bicara scales clinical operations and manufacturing.
Bicara initiated the pivotal FORTIFI-HN01 Phase 2/3 program (combination with pembrolizumab) and maintains a collaboration with MSD to supply pembrolizumab for combination cohorts. R&D spending increased materially to support clinical and manufacturing activity, and management expects existing cash to fund operations into the first half of 2029. The company disclosed pending litigation alleging inventorship of patents and reiterated that it will require additional funding over time to advance development and commercialization.